Alterity Therapeutics Ltd. (ATHE)
4.51
-0.03
(-0.66%)
USD |
NASDAQ |
Sep 08, 16:00
4.55
+0.04
(+0.89%)
Pre-Market: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 81.75M |
| 52 Week High (Daily) | |
| 52 Week Low (Daily) | |
| All-Time High (Daily) | |
| Year to Date Total Returns (Daily) | |
| 1 Month Total Returns (Daily) | |
| 1 Year Total Returns (Daily) | -12.77% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | |
| PS Ratio | -- |
| Price to Book Value | -- |
| EV to EBITDA | |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | |
| Financials | |
| Revenue (5 Year Growth) | |
| Revenue (Quarterly YoY Growth) | |
| EPS Diluted (5 Year Growth) | |
| EPS Diluted (Quarterly YoY Growth) | |
| Debt to Equity Ratio | -- |
| Return on Equity | |
| Return on Assets | |
| Risk | |
| Beta (5Y) | |
| Max Drawdown (5Y) | 96.94% |
Profile
| Alterity Therapeutics Ltd. engages in the business of research and development of therapeutic drugs designed to treat neurodegenerative diseases, focusing on Parkinsonian and other movement disorders. Its lead candidate, ATH434, is an oral small molecule drug designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. The company was founded by Geoffrey Paul Kempler on November 11, 1997 and is headquartered in Melbourne, Australia. |
| URL | http://alteritytx.com |
| Investor Relations URL | http://pranabio.com/investors/ |
| HQ State/Province | Victoria (VIC) |
| Sector | Health Care |
| Industry | Biotechnology |
| Equity Style | Small Cap Core |
| Next Earnings Release | N/A |
| Last Earnings Release | N/A |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Profile
| Alterity Therapeutics Ltd. engages in the business of research and development of therapeutic drugs designed to treat neurodegenerative diseases, focusing on Parkinsonian and other movement disorders. Its lead candidate, ATH434, is an oral small molecule drug designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. The company was founded by Geoffrey Paul Kempler on November 11, 1997 and is headquartered in Melbourne, Australia. |
| URL | http://alteritytx.com |
| Investor Relations URL | http://pranabio.com/investors/ |
| HQ State/Province | Victoria (VIC) |
| Sector | Health Care |
| Industry | Biotechnology |
| Equity Style | Small Cap Core |
| Next Earnings Release | N/A |
| Last Earnings Release | N/A |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |